Display options
Cite
Vaisman F, Momesso D, Bulzico DA, et al. Thyroid Lobectomy Is Associated with Excellent Clinical Outcomes in Properly Selected Differentiated Thyroid Cancer Patients with Primary Tumors Greater Than 1 cm. J Thyroid Res. 2013;2013:398194doi: 10.1155/2013/398194.
Vaisman, F., Momesso, D., Bulzico, D. A., Pessoa, C. H., da Cruz, M. D., Dias, F., Corbo, R., Vaisman, M., & Tuttle, R. M. (2013). Thyroid Lobectomy Is Associated with Excellent Clinical Outcomes in Properly Selected Differentiated Thyroid Cancer Patients with Primary Tumors Greater Than 1 cm. Journal of thyroid research, 2013398194. https://doi.org/10.1155/2013/398194
Vaisman, Fernanda, et al. "Thyroid Lobectomy Is Associated with Excellent Clinical Outcomes in Properly Selected Differentiated Thyroid Cancer Patients with Primary Tumors Greater Than 1 cm." Journal of thyroid research vol. 2013 (2013): 398194. doi: https://doi.org/10.1155/2013/398194
Vaisman F, Momesso D, Bulzico DA, Pessoa CH, da Cruz MD, Dias F, Corbo R, Vaisman M, Tuttle RM. Thyroid Lobectomy Is Associated with Excellent Clinical Outcomes in Properly Selected Differentiated Thyroid Cancer Patients with Primary Tumors Greater Than 1 cm. J Thyroid Res. 2013;2013:398194. doi: 10.1155/2013/398194. Epub 2013 Dec 23. PMID: 24455413; PMCID: PMC3884614.
Copy Download .nbib Format: NLM
Share it on

J Thyroid Res. 2013;2013:398194. doi: 10.1155/2013/398194. Epub 2013 Dec 23.

Thyroid Lobectomy Is Associated with Excellent Clinical Outcomes in Properly Selected Differentiated Thyroid Cancer Patients with Primary Tumors Greater Than 1 cm.

Journal of thyroid research

Fernanda Vaisman, Denise Momesso, Daniel A Bulzico, Cencita H C N Pessoa, Manuel Domingos Gonçalves da Cruz, Fernando Dias, Rossana Corbo, Mario Vaisman, R Michael Tuttle

Affiliations

  1. Endocrinology Service, Universidade Federal do Rio de Janeiro, Rua Rodolpho Paulo Rocco 255, Cidade Universitária Ilha do Fundão, 21941-913 Rio de Janeiro, RJ, Brazil ; Endocrinology Service, Instituto Nacional do Cancer, Praça da Cruz Vermelha 23, Centro, 20230-130 Rio de Janeiro, RJ, Brazil.
  2. Endocrinology Service, Universidade Federal do Rio de Janeiro, Rua Rodolpho Paulo Rocco 255, Cidade Universitária Ilha do Fundão, 21941-913 Rio de Janeiro, RJ, Brazil.
  3. Endocrinology Service, Instituto Nacional do Cancer, Praça da Cruz Vermelha 23, Centro, 20230-130 Rio de Janeiro, RJ, Brazil.
  4. Surgery Service, Universidade Federal do Rio de Janeiro, Rua Rodolpho Paulo Rocco 255, Cidade Universitária Ilha do Fundão, 21941-913 Rio de Janeiro, RJ, Brazil.
  5. Head and Neck Service, Instituto Nacional do Cancer, Praça da Cruz Vermelha 23, Centro, 20230-130 Rio de Janeiro, RJ, Brazil.
  6. Endocrinology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

PMID: 24455413 PMCID: PMC3884614 DOI: 10.1155/2013/398194

Abstract

Background and Objective. An individualized risk-based approach to the treatment of thyroid cancer is being extensively discussed in the recent literature. However, controversies about the ideal surgical approach remain an important issue with regard to the impact on prognosis and follow-up strategies. This study was designed to describe clinical outcomes in a cohort of low and intermediate risk thyroid cancer patients treated with thyroid lobectomy. Methods. Retrospective review of 70 patients who underwent lobectomy. Results. After a median follow-up of 11 years, 5 patients (5/70, 7.1%) recurred and 5 had a completion for benign lesions, while 60 patients (86%) continued to be observed without evidence for disease recurrence. Suspicious ultrasound findings were significantly more common in patients that had structural disease recurrence (100% versus 4.3%, P < 0.001). Furthermore, a rising suppressed Tg value over time was also associated with structural disease recurrence (80% versus 21.5%, P = 0.01). After additional therapy, 99% of the patients had no evidence of disease. Conclusions. Properly selected thyroid cancer patients can be treated with lobectomy with excellent clinical outcomes.

References

  1. Arq Bras Endocrinol Metabol. 2009 Dec;53(9):1167-75 - PubMed
  2. Thyroid. 1995 Jun;5(3):165-70 - PubMed
  3. Thyroid. 2012 Aug;22(8):778-83 - PubMed
  4. Thyroid. 1994 Fall;4(3):239-42 - PubMed
  5. J Natl Compr Canc Netw. 2010 Nov;8(11):1228-74 - PubMed
  6. Surgery. 1994 Dec;116(6):1036-40; discussion 1040-1 - PubMed
  7. Thyroid. 2009 Nov;19(11):1167-214 - PubMed
  8. J Clin Endocrinol Metab. 1995 May;80(5):1485-7 - PubMed
  9. J Endocrinol Invest. 2010 May;33(5):287-91 - PubMed
  10. Surgery. 1993 Dec;114(6):1050-7; discussion 1057-8 - PubMed
  11. Clin Endocrinol (Oxf). 2011 Jul;75(1):112-9 - PubMed
  12. J Endocrinol Invest. 2012;35(6 Suppl):10-5 - PubMed
  13. Am J Surg. 1997 Nov;174(5):462-8 - PubMed
  14. Clin Endocrinol (Oxf). 2012 Jul;77(1):132-8 - PubMed
  15. Ann Surg Oncol. 1996 Nov;3(6):534-8 - PubMed
  16. Surgery. 1987 Dec;102(6):1088-95 - PubMed

Publication Types